Pasar al contenido principal

EL INTERACTOMA DIFERENCIAL DEL RECEPTOR LRP1 EN CELULAS VASCULARES MUSCULARES ESPUMOSAS COMO FUENTE DE BIOMARCADORES DE RIESGO CORONARIO EN BIOPSIA LIQUIDA

PI21/01523

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, M.P.
Centro realización INSTITUTO DE INV. BIOMEDICAS BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martínez, Andrea
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Dandurand, Jany
  • Polishchuk, Anna
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Cenarro, Ana
  • Civeira, Fernando|||0000-0001-7043-0952
  • Bernabé, Amable
  • Viladés Medel, David|||0000-0002-3638-9703
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Patients with familial hypercholesterolemia (FH) exhibit a significant residual cardiovascular risk. A new cardiovascular risk factor is the susceptibility of individual LDL particles to aggregation. This study examined LDL aggregation and its relationship with LDL lipid composition and biophysical properties in patients with FH compared to controls. LDL aggregation was measured as the change in particle size, assessed by dynamic light scattering, after exposure to sphingomyelinase, which breaks down sphingomyelin in the LDL phospholipid layer. Dynamic light scattering and transmission electron microscopy showed that LDL in FH patients exhibited smaller size and greater susceptibility to aggregation. Biochemical analyses revealed a higher cholesteryl ester (CE)/ApoB100 ratio in LDL from FH patients. Differential scanning calorimetry showed that LDL from FH patients had higher transition temperatures, indicating a more ordered CE core. Fourier transform infrared spectroscopy revealed fewer flexible α-helices (1658 cm⁻ 1) and more stable α-helices (1651 cm⁻ 1) in ApoB100 of LDL from FH patients. These structural changes correlated with higher CE content and increased LDL aggregation. In conclusion, a more ordered CE core in smaller LDL particles, combined with a higher proportion of stable α-helices in ApoB100, promotes LDL aggregation in FH patients. These findings suggest ApoB100 conformational structure as a new potential therapeutic targets within LDL to reduce cardiovascular risk in FH patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reduced blood EPAC1 protein levels as a marker of severe Coronary Artery Disease: The role of hypoxic foam cell-transformed smooth muscle cells

  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Polishuck, Anna
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Piñero, Janet|||0000-0003-1244-7654
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Leta, Rubén|||0000-0003-4691-381X
  • Viladés Medel, David|||0000-0002-3638-9703
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Vascular smooth muscle cells loaded with cholesterol (foam-VSMCs) play a crucial role in the progression of human atherosclerosis. Exchange Protein Directly Activated by cAMP 1 (EPAC1) is a critical protein in the regulation of vascular tone, endothelial function, and inflammation. Our objectives were to identify proteins specifically secreted by foam human coronary VSMCs (foam-hcVSMC) to evaluate their potential as circulating biomarkers for diagnosing coronary artery disease (CAD), and to ascertain the mechanisms underlying their levels in the blood of patients with CAD. Methods and Results: Differential proteomics identified EPAC1 as a differential foamhcVSMC-secreted protein. Circulating EPAC1 levels were measured by ELISA in blood from 202 patients with suspected CAD who underwent coronary computed tomography angiography (CCTA). Blood EPAC1 levels were significantly lower in CAD patients compared to controls (p < 0.001). EPAC1 levels were reduced in both men and women with severe CAD (SIS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LRP1 immunotherapy enhances cardiomyocyte respiration by restricting cholesteryl ester accumulation in mitochondria

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Garcia, E.
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Polishchuk, A.
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Fernández-del-Rio, L.
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Samouillan, V.
  • Shirihai, Orion S.|||0000-0001-8466-3431
  • Liesa, M.
  • Enrich, Carlos|||0000-0003-0382-2993
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Antibodies (Abs) targeting the P3 sequence (Gly 1127 -Cys 1140) of LDL receptor-related protein 1 (anti-P3 Abs) inhibit the interaction between ApoB100 in cholesteryl ester (CE)-enriched lipoproteins and the CR9 domain in LDL receptor-related protein 1, preventing intracellular CE accumulation induced by a high-fat high-cholesterol (HFHC) diet in cardiomyocytes. This study examines (i) whether HFHC induces cholesterol accumulation in mitochondria, and impacts cardiac bioenergetics, and (ii) the effectiveness of anti-P3 Abs in mitigating HFHC-induced mitochondrial alterations. Cardiac tissue was homogenized, and mitochondria were isolated through subcellular fractionation. Thin layer chromatography demonstrated that HFHC induced the accumulation of CE in cardiac mitochondria, and that this process was significantly reduced by anti-P3 Abs. In line, transmission electron microscopy studies revealed that morphological changes induced by HFHC in cardiomyocyte mitochondria were reversed, at least in part, by anti-P3 Abs. Additionally, anti-P3 Abs promoted more extensive interactions between mitochondria and lipid droplets (LDs), accompanied by an increase in LD diameter and electrodensity in cardiomyocytes. Cardiac mitochondrial respiratory capacity assessed by Seahorse analysis showed that HFHC reduced CI/CIV and CII/CIV activity ratios, while anti-P3 Abs restored complex II/IV activity. In conclusion, by blocking CE uptake from lipoproteins, anti-P3 Abs reduce CE accumulation in the cardiomyocyte mitochondria and LDs, enhance bioenergetically favorable mitochondria/LD interactions, and improve cardiomyocyte respiratory function in hypercholesterolemic rabbits. These findings highlight the therapeutic potential of anti-P3 Abs in metabolic diseases by limiting CE loading of mitochondria and LDs in the heart and restoring cardiac bioenergetics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases

  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Polishchuk, Anna
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Solanelles Curco, Angels
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
Dietary lipids play a critical role in the development of cardiovascular disease and cancer by influencing key cellular processes. Lipoprotein and fatty acid receptors activate intracellular signaling pathways that promote tumor growth and vascular remodeling. A key event in both cancer and vascular diseases is the retention of low-density lipoproteins (LDL) and other lipoprotein particles by proteoglycans in the extracellular matrix (ECM) of atherosclerotic plaques and the tumor stroma. This retention facilitates lipoprotein modification processes. Dysregulated uptake of modified lipoproteins-particularly through receptors that are not downregulated by intracellular cholesterol levels-leads to excessive lipid accumulation within lipid droplets (LDs) and other intracellular organelles. The lipid and protein content of LDs and mitochondria determine the biophysical and functional characteristics of the crucial interactions between these suborgalles. In particular, lipid-derived mediators such as prostaglandins, leukotrienes, ceramides, oxidized fatty acids, and cholesterol can disrupt LD biogenesis and dynamics, impair mitochondrial function, and alter the expression, activity, and subcellular localization of proteins that regulate LD-mitochondria interactions. Dysfunctional communication between LDs and mitochondria contributes to the onset and progression of cancer and cardiovascular disease by disturbing cellular metabolism and energy homeostasis. Common LDL-related mechanisms in atherosclerosis and cancer have been summarized in Figure 1.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients

  • La Chica Lhoëst, Maria Teresa
  • Martínez, Andrea
  • García, Eduardo
  • Dandurand, Jany
  • Polishchuk, Anna
  • Benitez-Amaro, Aleyda
  • Cenarro, Ana
  • Civeira, Fernando
  • Bernabé, Amable
  • Vilades, David
  • Escolà-Gil, Joan Carles
  • Samouillan, Valerie
  • Llorente-Cortés, Vicenta
Patients with familial hypercholesterolemia (FH) exhibit a significant residual cardiovascular risk. A new cardiovascular risk factor is the susceptibility of individual LDL particles to aggregation. This study examined LDL aggregation and its relationship with LDL lipid composition and biophysical properties in patients with FH compared to controls. LDL aggregation was measured as the change in particle size, assessed by dynamic light scattering, after exposure to sphingomyelinase, which breaks down sphingomyelin in the LDL phospholipid layer. Dynamic light scattering and transmission electron microscopy showed that LDL in FH patients exhibited smaller size and greater susceptibility to aggregation. Biochemical analyses revealed a higher cholesteryl ester (CE)/ApoB100 ratio in LDL from FH patients. Differential scanning calorimetry showed that LDL from FH patients had higher transition temperatures, indicating a more ordered CE core. Fourier transform infrared spectroscopy revealed fewer flexible α-helices (1658 cm⁻1) and more stable α-helices (1651 cm⁻1) in ApoB100 of LDL from FH patients. These structural changes correlated with higher CE content and increased LDL aggregation. In conclusion, a more ordered CE core in smaller LDL particles, combined with a higher proportion of stable α-helices in ApoB100, promotes LDL aggregation in FH patients. These findings suggest ApoB100 conformational structure as a new potential therapeutic targets within LDL to reduce cardiovascular risk in FH patients., The development of this project was financially supported by FIS PI21/01523 (to C. V. L. C.) from the Instituto de Salud Carlos III (ISCIII) and cofinanced by ERDFs, as well as by Fundación BBVA Ayudas a Equipos de Investigación 2019 (to C. V. L. C.). Aleyda Benitez Amaro (A. B.-A.) is a postdoctoral fellow funded by Programme Contratos Predoctorales de Formación en Investigación en Salud (FI19/00205) from ISCIII and cofinanced by ERDFs. M. T. L. C. L. (FPU22/01888) and E. G. (FPU21/01173) are predoctoral fellows funded by the Spanish Ministry of Science, Innovation, and Universities in Spain. Our team is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to C. V. L. C. and D. V., and CB16/11/00451 to F. C. and A. C.) and CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 to J. C. E.-G), projects run by the Instituto de Salud Carlos III. Additionally, our group participates in the Redes de Investigación (Enfermedades Metabólicas y Cáncer RED2018-102799-T), a project funded by MINECO. We are also recognized by Generalitat de Catalunya (2021 SGR 00834). The IR-SANTPAU is a center of the CERCA Programme/Generalitat de Catalunya., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients

  • La Chica Lhoëst, Maria Teresa
  • Martínez, Andrea
  • Garcia, Eduardo
  • Dandurand, Jany
  • Polishchuk, Anna
  • Benitez-Amaro, Aleyda
  • Cenarro, Ana
  • Civeira, Fernando
  • Bernabé, Amable
  • Vilades, David
  • Escolà-Gil, Joan Carles
  • Samouillan, Valerie
  • Llorente-Cortes, Vicenta
Patients with familial hypercholesterolemia (FH) exhibit a significant residual cardiovascular risk. A new cardiovascular risk factor is the susceptibility of individual LDL particles to aggregation. This study examined LDL aggregation and its relationship with LDL lipid composition and biophysical properties in patients with FH compared to controls. LDL aggregation was measured as the change in particle size, assessed by dynamic light scattering, after exposure to sphingomyelinase, which breaks down sphingomyelin in the LDL phospholipid layer. Dynamic light scattering and transmission electron microscopy showed that LDL in FH patients exhibited smaller size and greater susceptibility to aggregation. Biochemical analyses revealed a higher cholesteryl ester (CE)/ApoB100 ratio in LDL from FH patients. Differential scanning calorimetry showed that LDL from FH patients had higher transition temperatures, indicating a more ordered CE core. Fourier transform infrared spectroscopy revealed fewer flexible α-helices (1658 cm⁻1) and more stable α-helices (1651 cm⁻1) in ApoB100 of LDL from FH patients. These structural changes correlated with higher CE content and increased LDL aggregation. In conclusion, a more ordered CE core in smaller LDL particles, combined with a higher proportion of stable α-helices in ApoB100, promotes LDL aggregation in FH patients. These findings suggest ApoB100 conformational structure as a new potential therapeutic targets within LDL to reduce cardiovascular risk in FH patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization

  • Benitez-Amaro, A.
  • Garcia, E.
  • La Chica Lhoëst, M.T.
  • Martínez, A.
  • Borràs, C.
  • Tondo, M.
  • Céspedes, M.V.
  • Caruana, P.
  • Pepe, A.
  • Bochicchio, B.
  • Cenarro, A.
  • Civeira, F.
  • Prades, R.
  • Escola-Gil, J.C.
  • Llorente-Cortés, V.
Background and aims: Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (Ldlr / hApoB100 Tg) and determine the potential LDL-related underlying mechanisms. Methods: Tg mice were fed an HFD for 21 days to induce atherosclerosis and then randomized into three groups that received a daily subcutaneous administration (10 mg/kg) of i) vehicle, ii) DP3 peptide, or iii) a non-active peptide (IP321). The in vivo biodistribution of a fluorescent-labeled peptide version (TAMRA-DP3), and its colocalization with ApoB100 in the arterial intima, was analyzed by imaging system (IVIS) and confocal mi-croscopy. Heart aortic roots were used for atherosclerosis detection and quantification. LDL functionality was analyzed by biochemical, biophysical, molecular, and cellular studies. Results: Intimal neutral lipid accumulation in the aortic root was reduced in the DP3-treated group as compared to control groups. ApoB100 in LDLs from the DP3 group exhibited an increased percentage of α-helix secondary structures and decreased immunoreactivity to anti-ApoB100 antibodies. LDL from DP3-treated mice were pro-tected against passive and sphingomyelinase (SMase)-induced aggregation, although they still experienced SMase-induced sphingomyelin phospholysis. In patients with familial hypercholesterolemia (FH), DP3 efficiently inhibited both SMase-induced phospholysis and aggregation. Conclusions: DP3 peptide administration inhibits atherosclerosis by preserving the α-helix secondary structures of ApoB100 in a humanized ApoB100 murine model that mimicks the hallmark of human hypercholesterolemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control

  • García, Eduardo
  • Gil, Pedro|||0000-0003-3707-7450
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Rodríguez, Claudia
  • Claudi, Lene
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garcia-Moll, Xavier|||0000-0001-7837-8378
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez, Antonio|||0000-0001-5528-1143
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism. To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization. This single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibitory Effects of LRP1-Based Immunotherapy on Cardiac Extracellular Matrix Biophysical Alterations Induced by Hypercholesterolemia

  • Samouillan, Valerie|||0000-0003-0571-3985
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Dandurand, Jany
  • Actis Dato, Virginia|||0000-0002-9071-8045
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Chiabrando, Gustavo
  • Enrich, Carlos|||0000-0003-0382-2993
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
The accumulation of lipids in cardiomyocytes contributes to cardiac dysfunction. The specific blockage of cardiomyocyte cholesteryl ester (CE) loading by antibodies (Abs) against the P3 sequence (Gly 1127 -Cys 1140) of the LRP1 receptor improves cardiac insulin sensitivity. The impact of anti-P3 Abs on high-fat diet (HFD)-induced cardiac extracellular matrix (ECM) biophysical alterations was analyzed. Both IrP (without Abs) and P3-immunized rabbits (with Abs) were randomized into groups fed either HFD or a standard chow diet. Cardiac lipids, proteins, and carbohydrates were characterized by Fourier transform infrared spectroscopy in the attenuated total reflectance mode. The hydric organization and physical structure were determined by differential scanning calorimetry. HFD increased the levels of esterified lipids, collagen, and α-helical structures and upregulated fibrosis, bound water, and ECM plasticization in the heart. The inhibitory effect of anti-P3 Abs on cardiac CE accumulation was sufficient to reduce the collagen-filled extracellular space, the level of fibrosis, and the amount of bound water but did not counteract ECM plasticization in the heart of hypercholesterolemic rabbits.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido|||0000-0003-1454-0916
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Benitez, Sonia|||0000-0003-3565-0743
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Crespo García, Javier|||0000-0001-8248-0172
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16-5p, miR-142-3p, miR-223-3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335-3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221-3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter.